RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Kiniksa Pharmaceuticals Stock

Kiniksa Pharmaceuticals ROCE 2024

Kiniksa Pharmaceuticals ROCE

-0.06

Ticker

KNSA

ISIN

BMG5269C1010

WKN

A2JMVJ

In 2024, Kiniksa Pharmaceuticals's return on capital employed (ROCE) was -0.06, a -332.12% increase from the 0.02 ROCE in the previous year.

Kiniksa Pharmaceuticals Aktienanalyse

What does Kiniksa Pharmaceuticals do?

Kiniksa Pharmaceuticals Ltd is a US biotech company founded in 2015 and headquartered in Lexington, Massachusetts. The company specializes in the development and commercialization of therapies for rare and chronic inflammatory diseases. Kiniksa Pharmaceuticals' business model is based on collaboration with leading scientists and clinicians to develop innovative solutions for patients with complex clinical needs. The company's products focus on various inflammatory diseases and have multiple candidates in the pipeline for different indications in clinical development. Kiniksa Pharmaceuticals has also focused on developing therapies for rare diseases. A key feature of the company is its high-throughput platform, which allows for the identification and validation of potential therapeutics in a short amount of time. Kiniksa Pharmaceuticals was founded in 2015 by former executives from Biogen and Vertex Pharmaceuticals who had extensive experience in the discovery and development of drugs for chronic inflammatory diseases. The company quickly received an initial funding of $60 million and has since sought additional financing to expand its technology platform and scientific expertise. Kiniksa Pharmaceuticals consists of several divisions, including the development division, which is responsible for the clinical development of therapeutics for rare and chronic inflammatory diseases. Another important division is product development, which specializes in the identification and validation of candidates for potential therapeutics. This includes the identification of biomarkers that can serve as indicators of drug effectiveness. Kiniksa Pharmaceuticals also has a marketing division responsible for the commercialization of already approved products. The products of Kiniksa Pharmaceuticals focus on the treatment of inflammatory diseases. One of the key candidates currently in clinical development is KPL-716, a potential monoclonal antibody that can be used for multiple indications, including cutaneous T-cell lymphoma and chronic obstructive asthma. Another important potential is the candidate Mavrilimumab, a potential monoclonal antibody that can be used for the treatment of giant cell arteritis and polymyalgia rheumatica. Other key candidates include KPL-404, a potential monoclonal antibody that can be used for the treatment of ulcerative colitis. Overall, Kiniksa Pharmaceuticals has a promising future by focusing on innovative products for rare and chronic inflammatory diseases. Kiniksa Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Kiniksa Pharmaceuticals's Return on Capital Employed (ROCE)

Kiniksa Pharmaceuticals's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Kiniksa Pharmaceuticals's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Kiniksa Pharmaceuticals's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Kiniksa Pharmaceuticals’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Kiniksa Pharmaceuticals stock

What is the ROCE (Return on Capital Employed) of Kiniksa Pharmaceuticals this year?

The ROCE of Kiniksa Pharmaceuticals is -0.06 undefined this year.

How has the ROCE (Return on Capital Employed) of Kiniksa Pharmaceuticals developed compared to the previous year?

The ROCE of Kiniksa Pharmaceuticals has increased by -332.12% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Kiniksa Pharmaceuticals?

A high Return on Capital Employed (ROCE) indicates that Kiniksa Pharmaceuticals has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Kiniksa Pharmaceuticals?

A low ROCE (Return on Capital Employed) can indicate that Kiniksa Pharmaceuticals has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Kiniksa Pharmaceuticals impact the company?

An increase in the ROCE of Kiniksa Pharmaceuticals can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Kiniksa Pharmaceuticals affect the company?

A decrease in ROCE of Kiniksa Pharmaceuticals can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Kiniksa Pharmaceuticals?

Some factors that can affect Kiniksa Pharmaceuticals's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Kiniksa Pharmaceuticals so important for investors?

The ROCE of Kiniksa Pharmaceuticals is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Kiniksa Pharmaceuticals take to improve the ROCE?

To improve the ROCE, Kiniksa Pharmaceuticals can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Kiniksa Pharmaceuticals pay?

Over the past 12 months, Kiniksa Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kiniksa Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Kiniksa Pharmaceuticals?

The current dividend yield of Kiniksa Pharmaceuticals is .

When does Kiniksa Pharmaceuticals pay dividends?

Kiniksa Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Kiniksa Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kiniksa Pharmaceuticals located?

Kiniksa Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kiniksa Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kiniksa Pharmaceuticals from 7/31/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/31/2024.

When did Kiniksa Pharmaceuticals pay the last dividend?

The last dividend was paid out on 7/31/2024.

What was the dividend of Kiniksa Pharmaceuticals in the year 2023?

In the year 2023, Kiniksa Pharmaceuticals distributed 0 USD as dividends.

In which currency does Kiniksa Pharmaceuticals pay out the dividend?

The dividends of Kiniksa Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Kiniksa Pharmaceuticals

Our stock analysis for Kiniksa Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kiniksa Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.